4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000899243-17-013806
Chief Executive Officer sold 50,000 shares at an average $16.26 ($812,859)
- Chief Executive Officer acquired 50,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Novak Rodger · Chief Executive Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2017-05-16 | Exercise or conversion : show line 1 in the form | +24,077 | $1.81 | $43,579 | 1,239,082 | D |
| 2017-05-16 | Sale : show line 2 in the form | −24,077 | $16.50 | $397,283 | 1,215,005 | D |
| 2017-05-17 | Exercise or conversion : show line 3 in the form | +25,923 | $1.81 | $46,921 | 1,240,928 | D |
| 2017-05-17 | Sale : show line 4 in the form | −25,923 | $16.03 | $415,577 | 1,215,005 | D |
| Open-market sales · 50,000 sh · avg $16.26 · $812,859 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2017-05-16 | Exercise or conversion : show line 5 in the form Stock Options (Right to Buy) | −24,077 | $1.81 | 2025-09-10 | 24,077 | 144,016 | D |
| 2017-05-17 | Exercise or conversion : show line 6 in the form Stock Options (Right to Buy) | −25,923 | $1.81 | 2025-09-10 | 25,923 | 118,093 | D |
Loading xslF345X03/doc4.xml…